Close Menu

Serimmune: Noah Nasser, Bill Welch

Aug 06, 2019

Goleta, California-based Serimmune has appointed Noah Nasser as CEO and Bill Welch to its board of directors.

Prior to Seriummne, Nasser served as chief commercial officer at Human Longevity. Before working at Human Longevity, Nasser served as chief commercial officer at Counsyl. In addition, he held leadership positions at AltheaDx and Verinata Health. 

Welch is currently a venture partner at Illumina Ventures. Before joining Illumina Ventures, Welch served as CEO at Trovagene. Prior to Trovagene, Welch was president and CEO at Sequenom. Before working at Sequenom, Welch served as CCO at Monogram Biosciences. Prior to Monogram, Welch held progressive management positions at Abbot Laboratories. 

More Like This

Apr 02, 2020

10x Genomics: Kim Popovits

10x Genomics has appointed Kim Popovits to its board of directors. Popovits is the former chairman, president, and CEO of Genomic Health. She started at Genomic Health in 2002 as president and chief operating officer, before becoming CEO in 2009 and chairman in 2012. The company was acquired by Exact Sciences in November 2019.

Prior to joining Genomic Health, Popovits held several management roles at Genentech, including senior vice president of marketing and sales where she led the commercialization of 14 new therapies. In addition to her board position at 10x Genomics, Popovits is currently a member of the boards of Kiniksa Pharmaceuticals and MyoKardia, and previously served on the board of ZS Pharma.  

Apr 02, 2020

Castle Biosciences: Miles Harrison

Castle Biosciences has appointed Miles Harrison to its board of directors effective immediately, expanding the size of the board to eight members. Harrison will stand for election for a three-year term at the company's 2020 annual meeting of stockholders.

Since February 2016, Harrison as served as the North American president and general manager of independent global dermatology company Galderma Laboratories. He has also served as vice president and general manager of Galderma's consumer business unit. Prior to Galderma, Harrison spent most of his career at Novartis, and has held multiple leadership positions of increasing responsibility across the consumer, oncology and pharmaceuticals businesses, most recently as vice president and head of global advocacy.

Apr 01, 2020

Biotheranostics: Matt Sargent

Biotheranostics has promoted its vice president of sales, Matt Sargent, to the position of chief commercial officer. In his new role, Sargent will be responsible for sales, marketing, market access, and customer service, and will lead the company's growth of its core tests: Breast Cancer Index and CancerTYPE ID. Sargent holds over 17 years of experience in the oncology diagnostic space during which he led the launch of Breast Cancer Index at Biotheranostics and the launch of the oncology division of Caris Life Sciences, where he served as vice president of oncology sales.

Apr 01, 2020

LexaGene: Eleanor Kolossovski

LexaGene has appointed Eleanor Kolossovski as director of product marketing. Kolossovski most recently served as senior global product manager at Qiagen. She has also held multiple sales and marketing positions at clinical diagnostic firms including BD, Roche, and Qiagen. 

Mar 31, 2020

Flagship Biosciences: Geoff Metcalf

Flagship Biosciences announced the hiring of Geoff Metcalf as VP of clinical diagnostics, where he will lead the creation and implementation of diagnostic tissue tests. Metcalf has worked in product development, sales and marketing, and business development at companies including Eli Lilly and Beckman Coulter. Most recently he was head of strategic planning at Siemens Diagnostics.

Metcalf earned a bachelor's degree in chemical engineering from Virginia Tech and a master of business administration degree from Harvard.

Mar 26, 2020

LexaGene: Steven Armstrong

LexaGene has appointed Steven Armstrong as senior director of operations as part of the firm's plans to oversee its submission for US Food and Drug Administration Emergency Use Authorization of its commercial technology and other regulatory approvals. Armstrong's career includes obtaining FDA and global regulatory approvals in over 100 countries for more than 50 devices. 

Mar 25, 2020

Qiagen: Thierry Bernard

Qiagen said this week that it has named Thierry Bernard as CEO. Qiagen's board has also resolved to propose Bernard for election as CEO and managing director at the company's next annual meeting in June. Bernard, who is also senior VP and head of molecular diagnostics at Qiagen, has served as the company's interim CEO since October, when long-time CEO Peer Schatz parted ways with the company. Bernard joined Qiagen in 2015. Prior to that he was senior executive VP of worldwide commercial operations at BioMérieux, where he also managed investor relations for the greater China region.

Bernard is "an outstanding leader who has performed impressively while guiding Qiagen through a period of significant change since taking on this role on an interim basis in October 2019," Håkan Björklund, chairman of Qiagen's supervisory board, said in a statement. "He is a strong and proven leader with extensive industry expertise and deep customer relationships. Most important, he has shown the energy and skill to drive Qiagen forward and has been a key leader in achieving the agreement for Qiagen to be acquired by Thermo Fisher Scientific in a transaction that remains on track for completion in the first half of 2021."

Mar 24, 2020

Scipher Medicine: Slava Akmaev

Scipher Medicine has appointed Slava Akmaev as its chief technology officer, a role that includes overseeing the company's data science and technology teams, ensuring efficient data on-boarding, quality control, and rapid analytics across Scipher's pipeline of precision diagnostics.

Akmaev is a leader in applying high-throughput molecular technology, machine learning, artificial intelligence, and data analysis within the life sciences and healthcare industry, and routinely publishes in the peer-reviewed scientific literature. Prior to joining Scipher, he was the senior vice president and chief analytics officer at Berg, where he cofounded and led Berg Analytics. Prior to that he helped commercialize four molecular diagnostic tests at Genzyme Genetics. 

Mar 23, 2020

Myriad Genetics: Louise Phanstiel, John Henderson

Myriad Genetics' board of directors has nominated Louise Phanstiel as its new chair. Phanstiel has served as a director at Myriad since September 2009, has chaired the audit committee and been a member of the nominating and governance committee. She has held various positions at insurer Anthem, and was a partner at PricewaterhouseCoopers. Phanstiel has previously served on the boards of Verastem and Inveresk Research Group.

John Henderson, meanwhile, has resigned as chair of Myriad's board, but will continue to serve as a director. "This change in the leadership of the board is a reflection of the changing environment in which Myriad Genetics operates," Henderson said in a statement. "While the company remains focused on providing critical health care information for the patient, there also is a need to ensure optimization of the processes, which ensure efficient delivery of results, while managing business operations effectively."

Mar 17, 2020

Roche: Jörg Duschmalé, Patrick Frost

Roche has elected Jörg Duschmalé and Patrick Frost to its board of directors, while Andreas Oeri and John Bell have stepped down after 24 and 19 years on the board, respectively. Oeri was the representative of the current shareholder pool.

Duschmalé is a fifth-generation descendant of Roche's founder, and he was a postdoctoral researcher in oligonucleotide chemistry at Roche from 2015 to 2018. Frost has worked at life insurance company Swiss Life in Zurich since 2006, first as Group Chief Information Office and now as Group CEO. He previously served as the global head of fixed income investment at Winterthur Insurance.
Mar 17, 2020

Thrive Earlier Detection: Matt Franklin, Sarah Larson, Semi Trotto

Thrive Earlier Detection has announced the appointment of Matt Franklin as its chief commercial officer, the appointment of Sarah Larson to its board of directors, and Semi Trotto's promotion to chief people officer.

Franklin holds more than 20 years of business, commercial, and strategic marketing experience in the diagnostics, life sciences, and technology industries. Most recently, he served as chief business officer at ArcherDx, where he was responsible for various business development activities. Prior to Archer, he held senior leadership roles at both Foundation Medicine and Boston Scientific.

Larson currently serves as partner and chief human resources officer at Third Rock Ventures where she is responsible for human resources and also provides guidance and counsel to the firm's portfolio companies, focusing on areas of human capital, leadership development, and culture creation. She has more than 20 years of experience in human resources and leadership development.

Trotto, a member of Thrive's founding management team, most recently served as senior vice president and head of human resources. Before joining Thrive, she held leadership positions in human resources at Editas Medicine, Baxalta, and Bristol-Myers Squibb. She has more than 20 years of experience in the field overall.

Mar 16, 2020

Oxford BioDynamics: Jon Burrows, Christian Hoyer Millar

Maryland-based Oxford BioDynamics has appointed Jon Burrows as group CEO, replacing Christian Hoyer Millar. Burrows currently works at consulting and clinical advisory firm Oncology Partners. He previously served as president and CEO of OncoPlex Diagnostics and as director of business development and interim head of Ventana Medical Systems' translational diagnostics business unit. After Roche acquired Ventana, Burrows served as director of pharma operations. 

Millar has served as OBD's CEO since cofounding the firm in 2007, and will now serve as executive chairman. 

Mar 13, 2020

NantHealth: Deanna Wise

NantHealth has named Deanna Wise to its board of directors. Wise serves as senior VP and CIO of Phoenix-based Banner Health. Prior to joining Banner a year ago, she was executive VP and CIO of Dignity Health, where she oversaw the implementation of a multi-site electronic health records system and a predictive analytics program.  

Mar 12, 2020

Sema4: Rachel Sherman

Genetic testing and informatics firm Sema4 has appointed Rachel Sherman to its board of directors.

Sherman is a former principal deputy commissioner of food and drugs at the US Food and Drug Administration. Her career at FDA spanned almost three decades and she oversaw HIV drug development, directed the Critical Path initiative, launched expedited review, and guided the establishment of the oncology center of excellence program.

She is currently a drug development, regulatory, and policy consultant at a firm she founded last year after retiring from FDA, and a lecturer at Harvard Medical School's Department of Population Medicine. She also serves on the board of Aptinyx, a pharmaceutical firm.

Sherman holds an MD from Mount Sinai School of Medicine and a master's degree in public health from Johns Hopkins University.

Mar 10, 2020

Thermo Fisher Scientific: Paul Parker

Paul Parker will join Thermo Fisher Scientific as VP of strategy and corporate development, starting April 15. He will join the company from Goldman Sachs, where he was co-chairman of global mergers & acquisitions and a member of the firm's partnership committee. Previously, he held operating and client relationship roles at Goldman Sachs, Barclays, Lehman Brothers, and JP Morgan. Parker has degrees from Harvard Business School and from the University of North Carolina at Chapel Hill.

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.